Related references
Note: Only part of the references are listed.Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
Malin S. Nilsson et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
Jianbiao Zhou et al.
HAEMATOLOGICA (2020)
Reactive Oxygen Species Drive Proliferation in Acute Myeloid Leukemia via the Glycolytic Regulator PFKFB3
Andrew J. Robinson et al.
CANCER RESEARCH (2020)
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy
Sean G. Rudd et al.
EMBO MOLECULAR MEDICINE (2020)
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
Jose Yelamos et al.
CANCERS (2020)
New drugs creating new challenges in acute myeloid leukemia
Ing S. Tiong et al.
GENES CHROMOSOMES & CANCER (2019)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
Mechanisms of drug resistance in acute myeloid leukemia
Jing Zhang et al.
ONCOTARGETS AND THERAPY (2019)
New Treatment Options for Acute Myeloid Leukemia in 2019
Marco Cerrano et al.
CURRENT ONCOLOGY REPORTS (2019)
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Rory M. Shallis et al.
BLOOD REVIEWS (2019)
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-B-dependent P-glycoprotein upregulation
Su-Fern Tan et al.
JOURNAL OF LIPID RESEARCH (2019)
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies
Sven Christian et al.
LEUKEMIA (2019)
The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells
Biniam Adane et al.
CELL REPORTS (2019)
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia
Nicolas Chapuis et al.
FRONTIERS IN ONCOLOGY (2019)
Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD
Anna J. Dellomo et al.
CANCER LETTERS (2019)
Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells
Li-Pin Kao et al.
JOURNAL OF LIPID RESEARCH (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Xun Gui et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
Dan Liao et al.
FRONTIERS IN PHARMACOLOGY (2019)
Recent drug approvals for acute myeloid leukemia
Catherine Lai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition
Amy N. Sexauer et al.
BLOOD (2019)
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
Thomas Oellerich et al.
NATURE COMMUNICATIONS (2019)
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Mattias Carlsten et al.
FRONTIERS IN IMMUNOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
Liangxian Cao et al.
MOLECULAR CANCER THERAPEUTICS (2019)
NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease
Ebru Aydin et al.
ONCOGENE (2019)
Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea et al.
BLOOD ADVANCES (2019)
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
Eric S. Winer et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
Silvia Maifrede et al.
BLOOD (2018)
IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
Remco J. Molenaar et al.
CLINICAL CANCER RESEARCH (2018)
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells
Dang Wu et al.
HAEMATOLOGICA (2018)
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Naval Daver et al.
LEUKEMIA (2018)
Exploiting an Asp-Glu switch in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia
Florence F. Wagner et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells
Dang Wu et al.
HAEMATOLOGICA (2018)
A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
Samuel John et al.
MOLECULAR THERAPY (2018)
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Haley E. Ramsey et al.
CANCER DISCOVERY (2018)
The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia
David B. Sykes
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration
Mi Deng et al.
NATURE (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
Daniel A. Pollyea et al.
NATURE MEDICINE (2018)
The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1
Kirsten M. Knecht et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Precision medicine in the treatment stratification of AML patients: challenges and progress
Ines Lohse et al.
Oncotarget (2018)
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects
Xia Li et al.
EBIOMEDICINE (2018)
DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages
Petra Mlcochova et al.
EMBO JOURNAL (2018)
Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia
Jason A. Powell et al.
BLOOD (2017)
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Ivana Gojo et al.
CLINICAL CANCER RESEARCH (2017)
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
Constanze Schneider et al.
NATURE MEDICINE (2017)
Genetic and epigenetic heterogeneity and the impact on cancer relapse
Ciaran Hassan et al.
EXPERIMENTAL HEMATOLOGY (2017)
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Nikolas Herold et al.
NATURE MEDICINE (2017)
Roles of PFKFB3 in cancer
Linlin Shi et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts
Christopher R. Marlein et al.
BLOOD (2017)
mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival
Yonghuai Feng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML
Mohammed Dany et al.
BLOOD (2016)
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy
Ruxanda Moschoi et al.
BLOOD (2016)
Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia
David B. Sykes et al.
CELL (2016)
NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML
Ashok Kumar Jayavelu et al.
EXPERIMENTAL HEMATOLOGY (2016)
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia
Sixuan Qian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Acid ceramidase is upregulated in AML and represents a novel therapeutic target
Su-Fern Tan et al.
ONCOTARGET (2016)
Current challenges in clinical development of targeted therapies: the case of acute myeloid leukemia
Elihu Estey et al.
BLOOD (2015)
Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications
Rebecca Kohnken et al.
MOLECULAR CANCER (2015)
The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development
Xunlei Kang et al.
NATURE CELL BIOLOGY (2015)
7Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Maria Teresa Esposito et al.
NATURE MEDICINE (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
The pentose phosphate pathway and cancer
Krushna C. Patra et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
Glutathione and mitochondria
Vicent Ribas et al.
FRONTIERS IN PHARMACOLOGY (2014)
Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling
Paul S. Hole et al.
BLOOD (2013)
N-Linked Glycosylation Supports Cross-Talk between Receptor Tyrosine Kinases and Androgen Receptor
Harri M. Itkonen et al.
PLOS ONE (2013)
Immune evasion in acute myeloid leukemia: current concepts and future directions
Ryan M. Teague et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells
Juliana Velez et al.
FRONTIERS IN ONCOLOGY (2013)
Beyond DNA repairs additional functions of PARP-1 in cancer
Alice N. Weaver et al.
FRONTIERS IN ONCOLOGY (2013)
Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis
Johan Aurelius et al.
BLOOD (2012)
The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of cell survival and death
James R. Van Brocklyn et al.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY (2012)
Effects of hypoxia and HIFs on cancer metabolism
Vera Mucaj et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
The Vpx Lentiviral Accessory Protein Targets SAMHD1 for Degradation in the Nucleus
Henning Hofmann et al.
JOURNAL OF VIROLOGY (2012)
Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages
Daniel Baitsch et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs
S. E. Fordham et al.
LEUKEMIA (2011)
Differentiation Therapy of Acute Myeloid Leukemia
Elzbieta Gocek et al.
Cancers (2011)
Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells
Paul S. Hole et al.
BLOOD (2010)
Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo
Amitava Sengupta et al.
BLOOD (2010)
An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome
Tariq I. Mughal et al.
CANCER TREATMENT REVIEWS (2010)
Challenges in Treating Older Patients with Acute Myeloid Leukemia
Lagadinou D. Eleni et al.
JOURNAL OF ONCOLOGY (2010)
Nox-generated ROS modulate glucose uptake in a leukaemic cell line
Cecilia Prata et al.
FREE RADICAL RESEARCH (2008)
Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site
Steve Bonello et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Oxygen radicals induce poly(ADP-ribose) polymerase-dependent cell death in cytotoxic lymphocytes
Fredrik B. Thoren et al.
JOURNAL OF IMMUNOLOGY (2006)
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
S Gasser et al.
NATURE (2005)
All trans retinoic acid in acute promyelocytic leukemia
L Degos et al.
ONCOGENE (2001)
Targeting ceramide metabolism - a strategy for overcoming drug resistance
A Sanchenkov et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
